The goal of this research is to understand the processes involved in excitotoxic degeneration of synapses using an animal model. Animal models for human neurodegenerative disease are of great value for exploring the cellular and biochemical mediators and molecular pathogenesis of a slowly progressive disease process. The slow channel congenital myasthenic syndrome (SCCMS) is caused by mutations that result in delayed closure of the ion channel of the acetylcholine receptor (AM) of the neuromuscular (NMJ). The delayed channel closure is associated with calcium overload and degeneration of the NMJ, AChR loss, and progressive muscle weakness. Thus, the SCCMS is a prototype for a hereditary excitotoxic disorder. Using transgenic mice technology and site-directed mutagenesis of AChR subunit coding sequences, we have developed the slow-channel transgenic mouse, an animal model for the SCCS that manifest all the features seen in the human disease. In this proposal, the investigator proposes to: (1) Determine whether slow-channel transgenic mice have reduced expression of neuromuscular synapse-specific genes. This will be accomplished by comparison of mRNA levels for the AChR subunit genes and other NMJ-specific genes between transgenic and control mice and between degenerating NMJ nuclei and remote from the NMJ nuclei; (2) Determine the cause(s) of the organellar damage and endplate myopathy in slow-channel mice. Three likely pathways of intracellular damage: activation of calcium-activated proteases, oxidative damage by free radicals, and apoptosis will be explored using a combination of specific antibody probes and stains to look for damaged proteins and DNA at the NMJ and genetic and pharmacological manipulation of these pathways to alter the course of the disease; and (3). Determine if quinidine can protect the slow-channel transgenic mice from endplate degeneration.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS036809-04
Application #
6539944
Study Section
Special Emphasis Panel (ZRG1-MDCN-2 (01))
Program Officer
Jacobs, Tom P
Project Start
1999-04-15
Project End
2004-03-31
Budget Start
2002-04-01
Budget End
2004-03-31
Support Year
4
Fiscal Year
2002
Total Cost
$204,825
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Neurology
Type
Schools of Medicine
DUNS #
168559177
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Zayas, Roberto; Groshong, Jason S; Gomez, Christopher M (2007) Inositol-1,4,5-triphosphate receptors mediate activity-induced synaptic Ca2+ signals in muscle fibers and Ca2+ overload in slow-channel syndrome. Cell Calcium 41:343-52
Vohra, Bhupinder P S; Groshong, Jason S; Zayas, Roberto et al. (2006) Activation of apoptotic pathways at muscle fiber synapses is circumscribed and reversible in a slow-channel syndrome model. Neurobiol Dis 23:462-70
Navedo, Manuel F; Lasalde-Dominicci, Jose A; Baez-Pagan, Carlos A et al. (2006) Novel beta subunit mutation causes a slow-channel syndrome by enhancing activation and decreasing the rate of agonist dissociation. Mol Cell Neurosci 32:82-90
Gomez, Christopher M; Maselli, Ricardo A; Groshong, Jason et al. (2002) Active calcium accumulation underlies severe weakness in a panel of mice with slow-channel syndrome. J Neurosci 22:6447-57
Restituito, S; Thompson, R M; Eliet, J et al. (2000) The polyglutamine expansion in spinocerebellar ataxia type 6 causes a beta subunit-specific enhanced activation of P/Q-type calcium channels in Xenopus oocytes. J Neurosci 20:6394-403